Marsh & McLennan saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 79 to 82.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Marsh & McLennan is within a buying range after climbing above a 235.50 buy point in a cup without handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
Top and bottom line growth moved higher last quarter. Earnings were up 11%, compared to 4% in the prior report. Revenue increased from 6% to 9%.
Marsh & McLennan holds the No. 6 rank among its peers in the Insurance-Brokers industry group. Ryan Specialty Holdings, Brown & Brown and Gallagher are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
